BioNTech's Founding Duo Builds a Successor While the Handover Stays Unsettled

?ahin and Türeci register Arife SE in Mainz for mRNA work, but BioNTech asset separation remains unresolved before their exit.

U?ur ?ahin and Özlem Türeci have settled on a name for the biotech venture they intend to build after leaving BioNTech: Arife SE. The choice, first reported by Bloomberg, gives shareholders their clearest signal yet about how the couple behind the world's first approved mRNA vaccine plan to spend their post-BioNTech years — and it lands at a moment when the mechanics of their exit remain anything but settled.

The two researchers will keep their BioNTech shareholdings, and Guido Oelkers is slated to take the chair of the management board on 1 February 2027. Until the end of 2026, however, ?ahin and Türeci remain in place, working to hand over a company they have already begun reshaping into an oncology specialist.

A €120,000 shell with a few hundred jobs in mind

Arife is registered with share capital of €120,000 — explicitly not an operating research budget, but the groundwork for a company expected to employ several hundred people. Its remit mirrors what the founders know best: research, development, manufacturing and commercialisation of new mRNA therapies, based in Mainz.

Under the plan, BioNTech would transfer selected mRNA technologies to the new entity in exchange for a minority stake and licensing fees. That interface is where the trouble sits. According to Handelsblatt, the separation of patents, active substances, financial resources and personnel has yet to be resolved at all, and with only about three months left before the founders' planned departure, an agreement could still fall apart.

The strain is already visible inside BioNTech. The company's own mRNA team is set to shrink from 150 to 120 staff, according to employee accounts, while hundreds of production workers are underutilised and on paid leave. For a business trying to prove its innovation does not rest on two names, the optics are awkward.

Regulatory win in Canada, clinical momentum in lung cancer

Against that internal backdrop, the operating story has produced genuine bright spots. On 17 September, Health Canada granted approval for Comirnaty, the Covid-19 vaccine adapted to the XFG variant, covering people aged six months and older — a timely boost ahead of the autumn season and a joint filing with Pfizer.

Oncology has supplied the more consequential news. Roughly two weeks after a setback in a colorectal cancer trial, updated data from the Phase 3 PRESERVE-003 study of gotistobart showed encouraging results in patients with advanced non-small cell lung cancer. The median overall survival in that trial came in at nearly double that seen with chemotherapy.

Analysts responded quickly. UBS reaffirmed its Buy rating and $135 price target on 16 September, while Berenberg raised its target from $132 to $140 the same day and kept its Buy recommendation.

Auditing the post-founder era

BioNTech is also tidying its governance for life after the founders. On 18 September the company disclosed that its supervisory board has nominated KPMG AG Wirtschaftsprüfungsgesellschaft as independent auditor for the 2027 financial year, subject to election by the annual general meeting.

With a market capitalisation of €22.52 billion, the group has the financial ballast to fund both the leadership transition and the later stages of its cancer pipeline.

The share price tells its own story about how investors are weighing the two narratives. The stock recently changed hands at €87.35, a modest premium to its 200-day moving average of €84.37. In a separate session it traded at €86.70, down 0.7% on the day, leaving it 18% below its 52-week high of €105.80 — a gap that suggests the market is watching the restructuring with a degree of caution rather than alarm.

What happens next hinges on whether a global pharmaceutical group and its visionary founders can divide a technology inheritance cleanly without damaging the pipeline left behind.